Table 2.
Effect of HESr on IPSS as add-on therapy in men under a1-blockers.
Group | n | Range | Mean (SD) | p | |
---|---|---|---|---|---|
HESr + a1-blocker | IPSS1 | 24 | 8–20 | 13.3 (3.9) | 0.006 |
IPSS2 | 24 | 8–22 | 11.3 (3.3) | ||
A1-blocker | IPSS1 | 23 | 8–20 | 13.5 (3.8) | 0.346 |
IPSS2 | 23 | 8–22 | 13.3 (3.5) |
HESr: hexanic lipidosterolic extract of Serenoa repens, IPSS: International Prostatic Symptoms Score, IPSS 1: IPSS at baseline, IPSS2: IPSS at 6 months, N: number of patients, SD: standard deviation.